Engineered Small Extracellular Vesicles as a FGL1/PD‐L1 Dual‐Targeting Delivery System for Alleviating Immune RejectionHsiang‐i Tsai, Hongbo Chen, Yingyi Wu et al.|Advanced Science|2021Cited by 70
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trialGuoying Liu, Yan‐Qun Xiang, Tian-Sheng Gao et al.|BMJ|2024Cited by 17
Engineered small extracellular vesicles as a FGL1/PD-L1 dual-targeting delivery system for alleviating immune rejectionHsiang‐i Tsai, Hongbo Chen, Yingyi Wu et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 9